Introducing Naveni target-specific assays for phosphorylated RTK’s: EGFR, HER2, PDGFR-beta, MET

Introducing Naveni target-specific assays for phosphorylated RTK’s: EGFR, HER2, PDGFR-beta, MET We are now launching target-specific Naveni in situ proximity ligation assays for phosphorylated receptor tyrosine kinases EGFR, HER2, PDGFR-beta and MET. The assays are based on dual epitope recognition by two primary Navenibodies, that generate an amplified signal when bound in close proximity. This…

Navinci and SciLife enters collaboration: Naveni in situ Proximity Ligation Assay technique will be provided by the SciLifeLab unit Affinity Proteomics Uppsala.

”We are delighted to partner with SciLifeLab and the Affinity Proteomics unit in Uppsala, as this allows the NaveniTM in situ proximity ligation assay technology to support the mission of SciLifeLab to enable life science research in Sweden to provide access to the latest key technologies. This collaboration will significantly benefit our academic customers that…

Navinci partners with Oncolab GmbH, Austria, to supply reagents to their P53 Prions – A novel biomarker test for circulating tumor cells

Navinci partners with Oncolab GmbH, Austria, to supply reagents to their P53 Prions – A novel biomarker test for circulating tumor cells This innovative test from OncoLab (Austria) identifies cancer cells via p53 prions and is based on the proprietary proximity ligation technology from Navinci. The test kits can be used with tissues, cells, and…